Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys
Autore:
Hotchkiss, CE; Stavisky, R; Nowak, J; Brommage, R; Lees, CJ; Kaplan, J;
Indirizzi:
Wake Forest Univ, Bowman Gray Sch Med, Comparat Med Sect, Winston Salem, NC 27157 USA Wake Forest Univ Winston Salem NC USA 27157 , Winston Salem, NC 27157 USA Novo Nordisk AS, Preclin Dev, Pathol, Malov, Denmark Novo Nordisk AS Malov Denmark k AS, Preclin Dev, Pathol, Malov, Denmark
Titolo Testata:
BONE
fascicolo: 1, volume: 29, anno: 2001,
pagine: 7 - 15
SICI:
8756-3282(200107)29:1<7:LPIBTA>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR MODULATOR; POSTMENOPAUSAL WOMEN; SERUM-CHOLESTEROL; MINERAL DENSITY; PARATHYROID HORMONE-(1-34); MACACA-FASCICULARIS; RHESUS-MONKEYS; RALOXIFENE; MASS;
Keywords:
levormeloxifene; selective estrogen receptor modulator (SERM); monkey; osteoporosis; ovariectomy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
54
Recensione:
Indirizzi per estratti:
Indirizzo: Hotchkiss, CE Natl Ctr Toxicol Res, Bionet Corp, Mail Code 915,3900 NCTR Rd, Jefferson, AR 72079 USA Natl Ctr Toxicol Res Mail Code 915,3900 NCTR Rd Jefferson AR USA 72079
Citazione:
C.E. Hotchkiss et al., "Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys", BONE, 29(1), 2001, pp. 7-15

Abstract

Levormeloxifene, a nonsteroidal selective estrogen receptor modulator (SERM), has been evaluated for its effects on bone in cynomolgus monkeys (Macaca fascicularis). Adult female monkeys were imported from Indonesia and randomized into six groups of 25-28 animals each (n = 158). Animals in one group were sham ovariectomized (sham) and received vehicle. Animals in the remaining five groups were ovariectomized and received either vehicle (ovx); 17beta -estradiol at 0.016 mg/kg (est); or levormeloxifene at 0.5 (Ll), I (L2), or 5 (L3) mg/kg. Lumbar spine and whole body bone mass were measured bydual-energy X-ray absorptiometry (DXA) pretreatment and at 6 and 12 monthsfollowing the initiation of treatment. Bone mass at the femoral neck was measured by peripheral quantitative computed tomography (pQCT) at 0 and 12 months. Serum markers of bone turnover, including bone-specific alkaline phosphatase (BSAP), osteocalcin (BGP), tartrate-resistant acid phosphatase (TRAP), and urinary collagen C-terminal extension peptides (CrossLaps), were measured at 0, 6, and 12 months. Ovariectomy resulted in an increase in these markers; the increase was prevented by estradiol or levormeloxifene. Estradiol or levormeloxifene inhibited loss of lumbar spine bone mineral density (BMD) following ovariectomy compared with untreated monkeys (ovx -5.0%; sham -0.4%; est +0.2%; Ll -3.6%, L2 -2.0%, L3 -2.5%). Estradiol, but not levormeloxifene, prevented loss of BMD at the femoral neck (ovx -7.4%; sham -3.1%; est -3.6%; Ll -8.0%, L2 -6.5%, L3 -7.8%), and whole body bone mineral content (BMC) (ovx -7.6%; sham -1.9%, est -2.9%; Ll -6.2%, L2 -6.1%, L3 -6.7%). Bone loss at each site was correlated with bone turnover as measured by serum and urine biomarkers. There was no dose effect of levormeloxifene. (C) 2001 by Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/04/20 alle ore 02:39:20